Date: 2014-08-12
Type of information: R&D agreement
Compound:
Company: Pfizer (USA - NY) 23andMe (USA - CA)
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Digestive diseases
Type agreement:
Action mechanism:
Disease: inflammatory bowel disease (IBD), Crohn’s disease, ulcerative colitis
Details: * On August 12, 2014, 23andMe, the leading personal genetics company announced an agreement with Pfizer in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. The collaboration represents an innovative effort for both companies designed to explore the underlying genetics of IBD and it is hoped that the effort will ultimately lead to potential new or improved treatments for IBD. All study participants will receive 23andMe’s Personal Genome Service® at no cost, including their ancestry analysis and uninterpreted raw genetic data. 23andMe will recruit individuals who are not current 23andMe customers and have also been diagnosed with Crohn’s disease or ulcerative colitis by a qualified physician. Study participants will need to consent to provide a DNA sample (saliva), answer online surveys, and agree to share their data with researchers. The study is currently open to U.S. residents only.
Financial terms:
Latest news:
